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Abstract 
Polymorphisms associated with BIN1 confer the second greatest risk for developing late onset 
Alzheimer’s disease. The biological consequences of this genetic variation are not fully 
understood, however BIN1 is a binding partner for tau. Tau is normally a highly soluble 
cytoplasmic protein, but in Alzheimer’s disease tau is abnormally phosphorylated and 
accumulates at synapses to exert synaptotoxicity. The purpose of this study was to determine 
if alterations to BIN1 and tau in Alzheimer’s disease promote the damaging redistribution of 
tau to synapses, as a mechanism by which BIN1 polymorphisms may increase risk of 
developing Alzheimer’s disease. We show that BIN1 is lost from the cytoplasmic fraction of 
Alzheimer’s disease cortex, and this is accompanied by the progressive mislocalization of 
phosphorylated tau to synapses. We confirmed proline 216 in tau as critical for tau interaction 
with the BIN1-SH3 domain and show that phosphorylation of tau disrupts this binding, 
suggesting that tau phosphorylation in Alzheimer’s disease disrupts tau-BIN1 associations. 
Moreover, we show that BIN1 knockdown in rat primary neurons to mimic BIN1 loss in 
Alzheimer’s disease brain, causes the damaging accumulation of phosphorylated tau at 
synapses and alterations in dendritic spine morphology. We also observed reduced release of 
tau from neurons upon BIN1 silencing, suggesting that BIN1 loss disrupts the function of 
extracellular tau. Together, these data indicate that polymorphisms associated with BIN1 that 
reduce BIN1 protein levels in the brain likely act synergistically with increased tau 
phosphorylation to increase risk of Alzheimer’s disease by disrupting cytoplasmic tau-BIN1 
interactions, promoting the damaging mis-sorting of phosphorylated tau to synapses to alter 
synapse structure, and by reducing the release of physiological forms of tau to disrupt tau 
function. 
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Main Text 
Introduction 
Tauopathies including Alzheimer’s disease (AD) are characterized by tau protein modifications 
that affect normal tau interactions and localization, and lead to the development of 
neurofibrillary pathology (Guo, Noble, and Hanger, 2017). The redistribution of highly 
phosphorylated and/or oligomeric tau species to pre- and post-synapses causes disruption of 
synaptic vesicle mobility and neurotransmitter release ( Zhou et al. 2017; McInnes et al. 2018), 
and excitotoxicity (Ittner et al., 2010; Li and Gotz, 2017), respectively. As a result, the 
accumulation of phosphorylated tau at synapses is closely linked with synapse loss and 
dementia in AD (Perez-Nievas et al., 2013; Hanseeuw et al., 2019). Developing a better 
understanding of the causes of tau protein redistribution to synapses may elucidate potential 
new treatment strategies for AD and related tauopathies.  
 
Recent genome-wide association studies (GWAS) have identified several gene variants that 
increase risk of developing AD. Of those identified to date, polymorphisms associated with 
bridging integrator 1 (BIN1) confer the second largest genetic risk factor for developing 
sporadic AD, after the apolipoprotein E4 allele (APOE4) (Seshadri et al., 2010; Hu et al., 2011; 
Wijsman et al., 2011; Lambert et al., 2013; Naj et al., 2014; Vardarajan et al., 2015). Rare 
variants in coding regions of BIN1 have been identified (Vardarajan et al., 2015), however the 
more common BIN1 variants are upstream of the gene and do not affect protein structure. 
However, these may affect tissue-specific splicing or expression of the cytoplasmic membrane-
binding BIN1 protein which is known to play important roles in endocytosis and subcellular 
trafficking (Prokic, Cowling, and Laporte, 2014). In support of this, expression of the longer 
neuronal isoforms of BIN1 are decreased and the shorter glial isoforms are increased in AD 
brain (Glennon et al. 2013; Holler et al. 2014; De Rossi et al. 2016).  
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Whilst most genetic variants that increase risk of AD affect -amyloid generation and/or 
clearance, BIN1 is relatively unusual in that its effects in AD appear to be mediated by tau 
(Chapuis et al., 2013; Wang et al., 2016). In AD brain, BIN1 may colocalize with 
neurofibrillary tangle-containing neurons (Holler et al., 2014), and is associated with elevated 
tau phosphorylation (Wang et al., 2016). Expression of BIN1 in a Drosophila model of AD 
was shown to modulate the toxicity of tau (Chapuis et al., 2013) and knockdown of BIN1 
promotes tau propagation between neurons (Calafate et al., 2016). Others have shown that 
BIN1 over-expression in mice causes microstructural changes in hippocampal circuits (Daudin 
et al., 2018) that are amongst the first to show tau pathology in AD (Daudin et al., 2018), 
suggesting that BIN1 may affect the development of AD by modulating tau effects at synapses, 
and possibly also synaptic activity-dependent tau release (Pooler et al., 2013). 
 
The effects of BIN1 on tau appear to be mediated by direct association between the two 
proteins. Interactions between BIN1 and tau have been demonstrated in cell models, 
Drosophila and mice (Chapuis et al., 2013; Sottejeau et al., 2015; Malki et al., 2017; Sartori et 
al., 2019). BIN1 contains a src homology 3 (SH3) domain through which it interacts with 
prolines (P) within PXXP motifs (Prokic, Cowling, and Laporte, 2014). Tau contains seven 
PXXP motifs in its proline-rich domain (Usardi et al., 2011), and the SH3 domain of BIN1 
interacts with the proline rich region of tau in a phosphorylation-dependent manner ( Chapuis 
et al., 2013; Sottejeau et al., 2015; Malki et al., 2017; Sartori et al., 2019). However, the 
mechanisms by which BIN1 affects tau to mediate pathological changes in tau proteins are not 
fully understood. The purpose of this study was to determine if alterations to BIN1 and tau in 
AD promote the damaging redistribution of tau to synapses, as a mechanism by which BIN1 
polymorphisms may increase risk of developing AD.  
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Materials and Methods 
Human Brain 
Braak-staged post-mortem human temporal cortex was obtained from the Medical Research 
Council London Neurodegenerative Diseases Brain Bank at King’s College London following 
ethical approval (Research Ethics Committee reference: 08/MRE09/38 + 5). 
Neuropathological assessment was performed according to standard criteria. Samples were 
classified as control (no history of neurodegenerative or psychiatric disease and age-related 
pathology only), moderate AD (clinical diagnosis of AD and Braak stage III-IV pathology) and 
severe AD (clinical diagnosis of AD and Braak stage V-VI pathology). Characteristics of these 
samples are summarized in Tables 1 and 2. 
 
Modification of BIN1 expression in primary neurons 
All animal work was conducted in accordance with the UK Animals (Scientific Procedures) 
Act 1986 and the European Directive 2010/63/EU under UK Home Office Personal and Project 
Licenses and with agreement from the King’s College London (Denmark Hill) Animal Welfare 
and Ethical Review Board. 
Pregnant female Sprague-Dawley rats were purchased from Charles River and were used 
within 1 day of delivery. Water and food were available (Picolab rodent diet 20; #5053; Lab 
Diet, St Louis, MO) ad libitum. Animals were housed at 19–22°C, humidity 55%, 12 h:12 h 
light: dark cycle with lights on at 07:30. Primary cortical neurons were dissected from 
embryonic day (E)18 male and female rats and were cultured as previously described (Pooler 
et al., 2012) on poly-D-lysine coated plates or glass cover-slips. Rat neurons were used since 
these provide a readily tractable cell model in which we can mimic findings from postmortem 
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human brain and they are a model in which tau biology has been extensively studied. Lentivirus 
shRNA targeting BIN1 from the RNAi consortium (TRCN0000088188), and a scrambled 
control sequence in the pLKO.1 vector, were purchased from Dharmacon Horizon (CO, USA). 
PAX2 and pMG.2 lentiviral packaging vectors were kind gifts from Dr Maria Jimenez-Sanchez 
(King’s College London). Human embryonic kidney (HEK293) cells cultured in Dulbecco’s 
modified eagle medium plus GlutaMAX (DMEM, Thermo Fisher Scientific, MA, USA) 
supplemented with 10 % (v/v) foetal bovine serum (FBS, Thermo Fisher Scientific) were 
transfected with PAX2, pMG.2, and shRNA lentivirus using lipofectamine 2000 (Invitrogen, 
CA, USA). After 24 hours, lentiviral particles were collected from culture medium, isolated 
and concentrated according to the manufacturer’s instructions. For lentiviral knockdown, 
neurons were cultured for 5 DIV, then treated with either BIN1 targeting shRNA, scrambled 
or control shRNA lentiviral particles for 24 hours, after which time the virus was removed and 
neurons further cultured until 21-23 days in vitro (DIV) prior to use. Alternatively, BIN1 was 
knocked down in primary neurons using Accell BIN1 siRNA smart pool (E-095528) purchased 
from Dharmacon Horizon Discovery UK. For these experiments, 19 DIV rat primary cortical 
neurons were transfected with 50 nM BIN1 or non-targeting control siRNA (Dharmacon 
Horizon Discovery) using lipofectamine 2000 for 96 hours at 37oC, after which time neurons 
were imaged or harvested. 
 
Tau enzyme-linked immunosorbent assay (ELISA) and cell viability assays 
Tau ELISAs were performed on Hank’s balanced salt solution (HBSS) without with Ca2+ and 
Mg2+ medium that had been incubated for 4 hours with 22-23 DIV primary neurons as we 
described previously (Croft et al., 2017). Lactate dehydrogenase amounts in the media of 
cultured neurons was determined as a measure of neuron heath, using an LDH cytotoxicity kit 
from Thermo Fischer Scientific according to the manufacturer’s instructions.  
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Immunofluorescence 
Immunofluorescence was performed as described (Schurmann et al., 2019), using 2 % (v/v) 
FBS (Life Technologies) in place of normal goat serum. Cells were incubated with primary 
antibodies against BIN1 (ab54764, Abcam), post-synaptic density 95 (PSD-95, D74D3, Cell 
Signaling), synaptophysin (sc7568, Santa Cruz, TX, USA), glial fibrillary acidic protein 
(GFAP, Agilent, ZO334) and microtubule associated protein 2 (MAP2, GTX82661, GeneTex), 
and the appropriate species of AlexaFluor-conjugated secondary antibodies (Life 
Technologies). Coverslips were mounted onto glass slides using pro-long diamond mounting 
media (Life Technologies). Labelled proteins were imaged using an Eclipse Ti2 inverted Nikon 
3D structured illumination microscope (N-SIM) and images reconstructed using Nikon 
Imaging Systems Elements software, or a Nikon Eclipse Ti-2 inverted microscope with Vt-
iSIM scan head and deconvolved using Nikon Imaging Systems Elements software.  
 
Analysis of synapses 
Primary neurons were fractionated to generate cytosol- and synapse- enriched fractions using 
a protocol modified from Frandemiche et al. (2014). Total, cytosolic and synaptoneurosome 
fractions were isolated from post-mortem temporal cortex as described by us previously (Perez-
Nievas et al., 2013). Equal protein amounts of total, synaptic and cytoplasmic fractions were 
immunoblotted.  
 
For analysis of dendritic spine structure, neurons at 22 DIV were transfected with enhanced 
green fluorescent protein (eGFP) eGFP-N2 plasmid (Clontech, Kyoto, Japan) using 
Lipofectamine 2000 for 24 hours, fixed and the GFP signal imaged using a Nikon Eclipse Ti-
2 inverted microscope with Vt-iSIM scan head. 3x3 large image stacks were acquired covering 
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the entire volume of the neuron, with 0.2 μm between each image in the Z plane. NeurolucidaTM 
software (MBF Bioscience, VT, USA) was used to trace neurons and detect, classify and 
quantify dendritic spines and perform the Scholl analysis. Neuronal complexity was 
determined by (sum of the terminal orders + number of terminals) * (total dendritic length / 
number of primary dendrites), where terminals is the number of branch endings, and terminal 
orders is the number of branches between the terminal and the cell body. 
 
Glutathione-S-transferase (GST) binding assays 
BIN1-SH3 cDNA generously provided by Isabelle Landrieu (University of Lille Nord de 
France) was cloned into pGEX5X1 vectors using sequence and ligation independent cloning 
(SLIC) (Hill and Eaton-Rye, 2014). The BIN1-SH3 domain was amplified from the original 
vector using primers 5’-TCG AGC GGC CGC ATC GTG ACA TGG GTC GTC TGG ATC 
TG-3’ and 5’-AAA CGC GCG AGG CAG ATC GTC AGT TAC GGC ACA CGC TCA GTA 
AAA TTC-3’, and pGEX5X1 was linearized using primers 5’-CTG ACG ATC TGC CTC 
GCG-3’ and 5’-GTC ACG ATG CGG CCG CTC-3’. SLIC products were used to transform 
BL21 E.Coli (New England Biolabs, MA, USA) by heat shock. DNA was purified using 
QIAgen spin miniprep kit (QIAgen, Hilden, Germany), and the cloning was confirmed by 
sequencing (Source Bioscience, Nottingham, UK), using stock primers to the GST plasmid. 
BL21 E.coli containing either BIN1-SH3-pGEX5X1 or empty vector pGEX5X1 were used to 
produce GST fusion proteins. Wild type (WT) human 2N4R tau and PxxP mutant tau plasmids 
have been described previously (Lau et al., 2016). These were expressed in HEK293 cells for 
24 hours after which time cells were lysed and the lysates used for GST pull-downs, which 
were performed as we described before ( Lau et al., 2016). 
 
SDS-PAGE and western blotting 
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Protein concentrations of samples was determined using a BCA protein assay kit (Thermo 
Fisher Scientific) and Ponceau Red staining of membranes. Equal protein amounts were 
electophoresed on 10 % tris-glycine-SDS-polyacrylamide gels, Nu-Page 4-12 % or 10 % bis-
tris gels (Invitrogen), transferred to 0.45 μm nitrocellulose membrane (Millipore, MA, USA), 
and immunoblotted using standard methods. Primary antibodies were BIN1 (99D, Millipore), 
GST (GE Healthcare, IL, USA), total tau (total human tau, Agilent), Tau-1 (Millipore), PHF1 
(Peter Davies, Donald and Barbara Zucker School of Medicine at Hofstra, Northwell), N-
methyl-D-aspartate subunit 2B (NR2B) (06-600, Millipore), -actin (ac15, Abcam), 
synaptophysin (sc17750, Santa Cruz), PSD95 (MAB 1596, Millipore), fyn (HPA023887, 
Sigma). Bound horseradish peroxidise (HRP)-conjugated secondary antibodies (GE 
Healthcare) were detected using enhanced chemiluminesence solutions (Thermo Fisher 
Scientific) and visualized using a chemi-doc imager (Bio-rad, CA, USA). Densitometric 
analysis was performed using FIJI.  
 
Data analysis and statistics 
Statistical tests were performed using GraphPad Prism 7.0 (CA, USA) or RStudio. Normality 
tests were performed on all data, and the appropriate statistical tests were then used to 
determine differences between experimental groups. Tests used and n numbers are provided 
for each experiment in the figure legends.  
 
Data Availability 
The data supporting this study are available in the manuscript and supplementary material 
and raw data will be made available on reasonable request following publication. Summary 
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statistics including exact P-values, F-values and degrees of freedom are included as a 
supplementary file. 
 
Results 
BIN1 loss in cytoplasmic fractions correlates with increased synaptic tau in AD 
brain 
In AD, highly phosphorylated tau is mislocalized to synaptic compartments (Perez-Nievas et 
al., 2013) where tau disrupts synapse function and mediates synaptotoxicity (Ittner et al., 2010; 
Li and Gotz, 2017; Zhou et al., 2017; McInnes et al., 2018). The longest neuronal isoform of 
BIN1 protein is reduced in end-stage AD brain ( Glennon et al., 2013; De Rossi et al., 2017). 
To determine if BIN1 is lost at earlier stages of AD, and if its loss is associated with changes 
in the distribution of tau, we isolated synaptoneurosomes (Perez-Nievas et al., 2013) from 
control (Braak stage 0-III), moderate (Braak stage III-IV) and severe (Braak stage V-VI) post-
mortem AD temporal cortex and examined total, cytosolic and synaptic fractions on western 
blots (Fig. 1). The integrity of synaptic proteins in these samples was first confirmed, as 
previously described (Bayes et al., 2014), by western blotting a subset of samples with an 
antibody against NR2B (Supplementary Fig.1 B-C) which shows acceptable levels of synaptic 
integrity is maintained in these tissues (Bayes et al., 2014), and showed no differences in 
synaptic integrity between groups. 
 
In total brain homogenates, we confirmed a trend towards reduction of BIN1 in severe relative 
to moderate stage AD and control tissues (Figure 1A, B), and significant increases in total and 
phosphorylated tau amounts with increasing disease severity (Figure 1A, C, D), as previously 
reported (Kurbatskaya et al., 2016). Protein amounts were normalized to neuron-specific 
enolase in the same sample prior to quantification to control for any effects of neuronal loss 
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and/or gliosis ( Kurbatskaya et al., 2016). Tau phosphorylation was detected using an antibody 
against tau phosphorylated at S396/404 (PHF1). The cytoplasmic and synaptoneurosome 
fractions isolated from the same brain samples were characterized to confirm their relative 
purity (Supplementary Fig. 1A). Blotting of these samples showed a significant accumulation 
of tau and phosphorylated tau in the synaptic compartment in severe AD brain, relative to 
moderate staged samples and controls (Figure 1E, G, H). Tau phosphorylated at S396/S404 
was found to accumulate at synapses in both moderate and severe stage Alzheimer’s disease 
relative to controls (Figure 1E, G, H). The accumulation of synaptic tau paralleled the loss of 
cytoplasmic tau (Figure 1I, K, L) suggesting that these results reflect tau mis-sorting from the 
cytoplasm to synapses. There were no differences in BIN1 levels in synaptoneurosomes 
between groups (Figure 1E, F). However, we found marked and significant losses of 
cytoplasmic BIN1 in both moderate and severe AD tissues (Figure 1I, J) that correlated 
positively with reductions in cytoplasmic tau (Figure 2A) and inversely with increased synaptic 
tau (Figures 2C,D). We also found negative correlations between levels of phosphorylated 
(pSer396/404, PHF1) tau and BIN1 in the cytoplasmic fraction (Figure 2B). There were also 
no significant correlations between total tau or phosphorylated tau and BIN1 amounts in either 
the total or synaptoneurosome fractions (Supplementary Figure 1G-J). Taken together, these 
data suggest that loss of cytoplasmic BIN1 may facilitate the mis-sorting of phosphorylated tau 
to the synapse.  
 
BIN1 knockdown causes synaptic accumulation of phosphorylated tau in neurons 
To model BIN1 loss and tau mislocalization to synapses in vitro, we silenced BIN1 in rat 
primary cortical neurons using lentivirus. We confirmed the efficiency of BIN1 knockdown by 
western blotting and proximity ligation assay (PLA) (Supplementary Fig. 2).  In control 
neurons, BIN1 and tau are found in fractions enriched in cytoplasmic and synaptic proteins 
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(Fig. 3A). N-SIM imaging of neuronal processes showed that BIN1 decorates MAP2-positive 
and MAP2-negative fibres (Figure 3B) and localizes in close proximity to pre-synaptic 
(synaptophysin) and post-synaptic (PSD95) markers, with a portion of BIN1 co-localizing with 
PSD95 (Figure 3C). Cultures were also immunolabelled with an antibody against GFAP which 
suggests that a small proportion of BIN1 is astrocytic (Supplementary Fig. 2I-J), in agreement 
with recent reports (Taga et al., 2019).  
 
We found that knockdown of BIN1 did not alter the total amount of tau or its phosphorylation 
in total cell lysates (Supplementary Fig. 2A-D). However, following BIN1 knockdown there 
was a significant increase in the amounts of phosphorylated, but not total or dephosphorylated, 
tau in synapse-enriched fractions relative to controls (Figure 3D-G). These data show that 
reducing BIN1 in neurons causes the accumulation of phosphorylated tau at synapses and 
suggest that the increased synaptic phospho-tau we observe in postmortem AD brain may result 
from tau mislocalisation from the cytoplasm upon the loss of cytoplasmic BIN1.  
 
When bound to tau, the non-receptor tyrosine kinase, Fyn, is trafficked to the post-synapses 
where it is believed to mediate -amyloid toxicity in AD (Ittner et al., 2010).  We previously 
showed that the Fyn-SH3 domain also binds preferentially to proline 216 in tau ( Usardi et al., 
2011; Pooler et al., 2012). We therefore examined the localisation of Fyn in synaptic fractions 
following BIN1 knockdown. Our data suggest that there is no competition between BIN1 and 
Fyn for binding to tau since we found no alterations in synaptic fyn amounts in neurons treated 
with BIN1 shRNA (Figure 3H). 
 
The interaction of BIN1 with tau is reported to be regulated by tau phosphorylation and via 
direct association of the BIN1-SH3 domain and the proline-rich region of tau (Sottejeau et al., 
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2015; Lasorsa et al., 2018). To confirm this, we generated GST-BIN1-SH3 constructs 
(Supplementary Fig. 3A) and we used these and GST-only constructs in binding assays using 
lysates from HEK293 cells transfected with wild-type human 2N4R tau, mutant tau constructs 
or empty vector. The mutant tau constructs are human 2N4R tau in which a single proline (P) 
in each PXXP motif is mutated to alanine (Supplementary Fig. 3B), as we reported previously 
(Lau et al., 2016). Immunoblotting of BIN1-SH3-GST pull-downs with an antibody against 
tau confirmed that the BIN1-SH3 domain binds human 2N4R tau (Supplementary Fig. 3A, Fig. 
4A, B). Analysis of BIN1-SH3 binding to mutant relative to WT human tau showed that P216 
is important for the tau-BIN1 interaction. The amount of P216A tau bound to BIN1-SH3 was 
significantly decreased relative to WT tau. There were no significant differences relative to 
WT in tau binding to BIN1-SH3 when any other proline residue was mutated to alanine (Fig. 
4A, B).   
 
We next confirmed that increasing tau phosphorylation, to mimic tau modifications in 
Alzheimer’s disease, affects the interaction of tau with BIN1 in cultured primary rat neurons. 
Cells were treated for 4 hours with 50 nM okadaic acid (OA), a protein phosphatase inhibitor 
that prevents removal of phosphate from residues throughout the tau molecule to allow efficient 
tau phosphorylation  (Van Dolah and Ramsdell, 1992; Pooler et al., 2012) (Fig. 4C). GST 
pulldowns with lysates from these cells confirmed that phosphorylated tau shows only trace 
amounts of binding to BIN1-SH3-GST when compared to lysates from vehicle-treated cells 
(Figure 4D). When tau was dephosphorylated upon application of 25 mM of the glycogen 
synthase kinase-3 (GSK3) inhibitor lithium chloride (LiCl) (Stambolic, Ruel, and Woodgett, 
1996; Pooler et al., 2012) (Figure 4E-F), or 20 μM of the casein kinase-1 (CK1) inhibitor IC261 
(Pooler et al., 2012) (Supplementary Fig. 4), the amount of tau pulled down by BIN1-SH3 was 
similar to controls. GSK3 and CK1 inhibitors were used to modulate tau phosphorylation since 
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these kinases phosphorylate tau throughout the protein (Guo, Noble, and Hanger, 2017), and 
phosphorylation of tau sites distal and proximal to P216 mediate tau interactions with BIN1-
SH3 (Sottejeau et al., 2015; Lasorsa et al., 2018). These data confirm and extend previous 
findings to show that BIN1-SH3 interacts with P216 in tau, predominantly when tau is 
dephosphorylated. Taken together, our data suggest that tau phosphorylation in Alzheimer’s 
disease may disrupt cytoplasmic BIN1-tau interactions and allow unbound tau to mislocalize 
to synapses. 
 
Loss of BIN1 alters spine morphology and reduces tau release from neurons 
Synaptic tau is closely linked with the release and propagation of modified tau proteins in 
Alzheimer’s disease and related tauopathies (Guo, Noble, and Hanger, 2017; Yamada, 2017). 
However, the release of soluble tau species in physiological conditions allows important 
signalling roles of extracellular tau (Gomez-Ramos et al., 2008; Pooler et al., 2013), and this 
tau function may be lost in Alzheimer’s disease (Croft et al., 2017).  
 
Tau release is predominantly mediated by synaptic activity and modulating BIN1 expression 
affects dendritic spine morphology and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor-mediated synaptic transmission via changes in AMPA receptor surface 
expression and trafficking (Daudin et al., 2018; Schurmann et al., 2019). Since we and others 
have previously shown that neuronal depolarization and stimulation of AMPA receptors 
mediates endogenous tau release (Pooler et al., 2013; Croft et al., 2017), we examined the 
effects of BIN1 knockdown by shRNA on synapse morphology and tau release. Examination 
of neurons by iSIM showed that BIN1 knockdown affects synaptic morphology in 23 DIV 
primary neurons exogenously expressing eGFP. BIN1 knockdown did not cause any alterations 
in dendritic spine length, volume or density (Figure 5A-D), but resulted in significant increases 
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in the diameter of spine heads and necks (Figure 5E-F) and a reduced head:neck diameter ratio 
(Figure 5G). When spine morphologies were examined, BIN1 knockdown had no effect on the 
proportion of immature stubby or thin spines (Figure 6H,I), but significantly reduced the 
proportion of filopodia (Figure 5K) and increased the proportion of mature mushroom spines 
(Figure 6J), which are relatively stable and have a high density of AMPA receptors (Hanley, 
2008; Lee, Soares, and Beique, 2012; Woolfrey and Srivastava, 2016). The structure and 
density of dendritic spines varies according to branch order of the neurite, and Scholl analysis 
(Supplementary Fig. 5) showed that BIN1 knockdown increases branching of dendrites and 
increases neuronal complexity which may contribute to the difference in spine structure we 
observe since spines on all branches of neurites were quantified.  
 
To determine if BIN1 knockdown affects tau release, tau content in culture medium from 21 
DIV neurons treated with BIN1 and control shRNA was measured by ELISA and normalized 
to the total amount of tau in neurons from the same culture well, as we reported previously 
(Croft et al., 2017). BIN1 knockdown caused a significant reduction in basal tau release 
without affecting the amount of intracellular tau (Figure 6A-C). BIN1 knockdown followed by 
depolarization of neurons with potassium chloride (KCl) to stimulate tau release (Pooler et al., 
2013; Croft et al., 2017), also significantly reduced tau release relative to controls (Figure 6D-
F). The observed changes in tau release were not due to cell toxicity since there were no 
alterations in lactate dehydrogenase content in medium between conditions (Figure 6G). Thus, 
BIN1 knockdown results in alterations in synapse morphology and reduces basal and 
stimulated tau release. Our findings therefore suggest that since BIN1 knockdown affects tau 
release, loss of BIN1 in AD will disrupt the functions of extracellular tau in addition to allowing 
phosphorylated tau to mislocalise to synapses and exert toxicity. Our data provide novel 
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insights into the mechanisms by which BIN1 polymorphisms may increase risk of Alzheimer’s 
disease. 
 
Discussion  
BIN1 is closely linked with tau abnormalities that underlie the progression of sporadic AD ( 
Chapuis et al., 2013; Calafate et al., 2016; Dourlen et al., 2019; Sartori et al., 2019). Our results 
suggest that BIN1 and tau interact predominantly when tau is dephosphorylated in the 
cytoplasm and that altered tau phosphorylation, together with BIN1 loss in AD, allows tau to 
be mislocalised to synapses where it is detrimental to synapse health. In support of this we 
found that P216 of tau interacts with the BIN1-SH3 and that interactions between these two 
proteins are disrupted when tau phosphorylation is increased in primary neurons. Our results 
also indicated that there may be some loss of tau interactions with BIN1-SH3 when tau proline 
219 was mutated to alanine. Notably, even when an apparent (but not statistically validated) 
outlier was removed from this analysis, binding of BIN1-SH3 with P219A mutant tau was not 
significantly reduced. However, others have reported that proline residues 216 and 219 of tau 
are in direct contact with BIN1 (Lasorsa et al., 2018). Our findings also showed that treatment 
with okadaic acid to increase tau phosphorylation effectively abolished tau interactions with 
BIN1. This is in-keeping with observations of tau interactions with other SH3 domain-
containing proteins such as fyn (Reynolds et al., 2008; Usardi et al., 2011; Pooler et al., 2012). 
Nevertheless, it is somewhat surprising that the binding of tau with BIN1 is not increased from 
baseline when tau is dephosphorylated since a degree of tau phosphorylation is expected in 
basal cell culture conditions. Future experiments using tau phosphomimics in which tau 
residues are mutated to mimic permanent phosphorylation or dephosphorylation, or conducting 
dose response experiments with tau phosphorylation modulators, will be useful to fully 
examine the effects of tau phosphorylation on its interactions with BIN1.  
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Loss of BIN1 from Alzheimer’s disease cytoplasm at moderate and severe stages of disease 
was accompanied by accumulation of phosphorylated tau in synaptic compartments. The 
average age of patients classified as “moderate” AD on the basis of Braak stage was found to 
be significantly higher than those with severe AD, and this may indicate that our “severe” AD 
group consisted of cases with increased resilience to the accumulation of AD pathology. Our 
analysis of the relationship between phosphorylated tau and BIN1 subcellular distributions was 
conducted independently of Braak stage and therefore we do not consider this to confound our 
findings.  However, it could be of interest to examine the relationship between tau and BIN1 
further in well-matched resilient and susceptible populations in future studies.  
 
To directly ascertain the effects of BIN1 loss on tau localization, we knocked down BIN1 in 
rat primary neurons and showed that this caused an accumulation of phosphorylated tau at 
synapses. This finding is in agreement with previous reports that over-expression of BIN1 in 
mice expressing human tau leads to a reduced number of somatodendritic tau inclusions 
(Sartori et al., 2019). This is an important concept since alterations in the trafficking and normal 
positioning of tau are considered to be early pathogenic changes in Alzheimer’s disease 
(Zempel and Mandelkow, 2014; Zempel and Mandelkow, 2015; Guo, Noble, and Hanger, 
2017). We also investigated the effects of BIN1 knockdown on synapse structure and tau 
release, since in addition to promoting the spread of tau pathology (Yamada, 2017), synapse 
function is important for the release of physiological forms of tau and therefore the signalling 
functions of extracellular tau (Gomez-Ramos et al., 2008). We show here that BIN1 
knockdown affects the morphology of dendritic spines, a feature closely linked with synapse 
function (Chidambaram et al., 2019). BIN1 knockdown caused an increased abundance of 
spines with a larger head and neck diameter, and a higher ratio of mature mushroom spines to 
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immature filopodia. Although in these experiments we transduced cells with BIN1 shRNA at 
DIV5, a time at which neurons and synapses are still developing, Sartori et al. (2019) have 
reported that BIN1 is not expressed in vitro until DIV14. Therefore, the alterations we observe 
in synapse morphology are not expected to have occurred as a result of any developmental 
roles of BIN1. In support of this, BIN1 over-expression in mice results in the opposite changes 
to spines, leading to structural alterations in the hippocampus and memory deficits (Daudin et 
al., 2018). Mushroom spines are considered to be more stable and in general, as spine size 
increases the number of AMPA receptors on the spine increases, promoting synaptic strength 
(Hanley, 2008; Lee et al., 2012; Woolfrey and Srivastava, 2016). This may appear to be in 
contrast with our assertion that BIN1 knockdown promotes synapse damage by directing 
phosphorylated tau into synapses. However, synapse enlargement is reported to occur in the 
early stages of neurodegeneration in AD (DeKosky and Scheff, 1990) as a compensatory 
mechanism for the pre-synapse loss occurring early in the disease process. A similar 
mechanism at the post-synapse could explain the increased spine diameter we report here. It is 
also possible that the effect of altering BIN1 expression on dendritic spines is independent of 
its binding to tau. Schurmann et al. (2019) report that BIN1 modulates vesicle trafficking from 
recycling endosomes to the cell surface thereby altering the surface localization of AMPA 
receptors at the post-synapse. Hence alterations in vesicle trafficking may be another 
mechanism by which BIN1 alters the structure of dendritic spines.  
 
Finally, we demonstrate that reducing BIN1 expression reduced tau secretion from neurons, 
both in basal conditions and following neuronal depolarization. We previously showed that tau 
released from primary neurons is largely intact, dephosphorylated (Pooler et al., 2012), and 
others have shown that this form of extracellular tau has important trans-cellular signaling 
functions (Gomez-Ramos et al., 2008) distinguishing it from the aggregated, cleaved and 
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highly phosphorylated tau species implicated in trans-synaptic tau spread/propagation (Wu et 
al., 2016). Our results therefore suggest that BIN1 loss in Alzheimer’s disease could reduce 
the availability of extracellular tau, resulting in a loss of extracellular tau function. 
 
In conclusion, our data demonstrate that BIN1 binds in a tau phosphorylation-dependent 
manner to P216 of tau. We find that BIN1 is lost in AD cytoplasm, and that this correlates with 
tau accumulation in synapses and its loss from the cytoplasm. Modelling the loss of BIN1 in 
AD in primary neurons showed that when BIN1 is knocked down, phosphorylated tau 
accumulates at synapses. We also see that BIN1 loss causes alterations to synapse structure 
and disrupts tau release. We hypothesize that disruptions to BIN1 proteins in AD affect normal 
tau functions in the extracellular space and promote phosphorylated tau-mediated 
synaptotoxicity. These data provide a potential mechanism by which polymorphisms near BIN1 
may increase AD risk.  
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Figure 1. BIN1 and tau are lost from the cytoplasm and this is associated with 
accumulation of phosphorylated tau at synapses in AD temporal cortex. A) Total 
homogenates from temporal cortex of control (Braak stage 0-III), moderate (Braak stage III-
IV) and severe (Braak stage V-VI) AD brain were western blotted using antibodies against 
BIN1, total tau, phosphorylated tau (PHF1, pSer396/404) and neuron specific enolase (NSE) 
as a loading control. Bar charts show quantification of B) BIN1, C) tau amounts and D) tau 
phosphorylated at Ser396/404 (PHF1).  Data shown are mean ± S.E.M. expressed as fold 
average control. n=13 per group (BIN1), 14 per group (tau) or 12 per group (PHF1). Following 
D’Agostino and Pearson normality testing, data were analysed using a one-way ANOVA with 
Holm-Sidak’s multiple comparisons test. E) Synaptoneurosomes isolated from the same 
temporal cortex samples were immunoblotted with the same antibodies. Bar charts show 
quantification of F) BIN1, G) tau, and H) PHF1 in synaptoneurosome fractions following 
normalisation.  Data are mean ± S.E.M. expressed as fold average control. n=15 per group 
(BIN1 and tau) or 12 per group (PHF1). Following D’Agostino and Pearson normality testing, 
data was analysed using non-parametric Kruskal-Wallis test with Dunn’s multiple comparison 
test. I) The cytoplasmic fraction was blotted as above with antibodies against BIN1, tau, PHF1 
and NSE. Bar charts show quantification of J) BIN1, K) tau and L) tau phosphorylated at 
Ser396/404 (PHF1) in the cytoplasmic fraction following normalisation to NSE in the same 
sample.  Data are mean ± S.E.M. expressed as fold mean control. n=11 per group (BIN1) or 12 
per group (tau and PHF1). Following D’Agostino and Pearson normality testing, BIN1 data 
was analysed using non-parametric Kruskal-Wallis test with Dunn’s multiple comparison test 
and tau data using a one-way ANOVA with Holm-Sidak’s multiple comparisons test. *p<0.05, 
** p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 2. Loss of BIN1 correlates with loss of cytoplasmic tau and increased synaptic tau 
in AD temporal cortex. Correlation analysis of A) BIN1 and tau amounts and B) BIN1 and 
phosphorylated (pSer396/404, PHF1) tau amounts in the cytoplasmic fractions showing a 
strong positive correlation between BIN1 and total tau, a negative correlation between BIN1 
and phosphorylated tau (n=38), and strong negative correlations between C) cytoplasmic BIN1 
and synaptic tau (n=38), and D) cytoplasmic BIN1 and synaptic tau phosphorylated at 
Ser396/404 (PHF1) (n=36). Colours represent control (green), moderate (blue) and severe 
(purple) AD samples. 
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Figure 3: BIN1 knockdown in neurons increases the abundance of phosphorylated tau at 
synapses. A) Proteins from 22 DIV primary cortical neurons were biochemically fractionated 
using a synaptosome fractionation protocol into total, synaptic protein- (syn) and cytoplasmic 
(cyto) protein-enriched fractions which were western blotted with antibodies against PSD95, 
tubulin, tau and BIN1. Blots show the presence of BIN1 and tau in all fractions and an 
enrichment of PSD-95 in the synaptic relative to the cytosolic fraction. B) N-SIM super 
resolution images of primary cortical neurons immunolabelled with antibodies against BIN1 
(ab54764, pink) and the dendritic marker MAP2 (blue) showing that BIN1 is present within 
dendrites and axons in cultured neurons.  C) N-SIM super-resolution images show close 
  
 30 
associations and some colocalization of BIN1 (ab54764, blue) with the pre-synaptic marker 
synaptophysin (green) and the post-synaptic marker PSD95 (red). D) Lysates from primary 
cortical neurons transduced with scrambled control shRNA (Scr) lentivirus or BIN1 shRNA 
(BIN1) lentivirus at 5 DIV and biochemically fractionated at 22 DIV as above were 
immunoblotted with antibodies against BIN1, total tau, tau phosphorylated at Ser396/404 
(PHF1), tau dephosphorylated at Ser199/202/Thr205 (Tau-1), Fyn kinase and PSD95. Bar 
charts show quantification of synaptic E) total tau, F) tau phosphorylated at Ser396/404 
(PHF1), G) dephosphorylated tau (Tau-1) and H) fyn protein amounts.  Data were normalised 
to the synaptic marker PSD95 in the same sample and are expressed as percentage mean control 
(scrambled shRNA). Data are mean ± S.E.M. and were analysed using Mann-Whitney test. 
n=4-5, **p<0.01. 
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Figure 4: BIN1 and tau interact via BIN1-SH3 and P216 in tau in a phosphorylation-
dependent manner.  A) HEK293 cells were transfected with wild-type 2N4R tau (WT) or 
PxxP mutant tau constructs in which a single proline residue at site 176, 182, 200, 206, 213, 
216, 219 or 223 was mutated to alanine to disrupt the PxxP sequence. Proteins in lysates from 
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HEK293 cells (input) were pulled down with BIN1-SH3-GST beads, and western blotted with 
antibodies against total tau or GST. B) The amount of WT or PXXP mutant tau pulled down 
by BIN1-SH3-GST was quantified and the bar chart shows this data relative to WT 2N4R tau 
(control). When P216 was mutated to alanine, tau binding to BIN1-SH3 was significantly 
reduced (** p<0.001). Following D’Agostino and Pearson normality testing, data were 
analysed using non-parametric Kruskal-Wallis test and Dunn’s multiple comparisons test. Data 
shown are mean ± S.E.M, n=9. C) Primary cortical neurons were treated with either vehicle (-
) or 50 nM okadaic acid (OA,+) for 4 hours. Proteins were pulled down from primary neuron 
lysates with BIN1-SH3-GST. Western blots of neuronal lysates (input) with antibodies against 
total tau, tau phosphorylated at Ser394/404 (PHF1) and tau dephosphorylated at 
Ser199/202/Thr 205 (Tau-1) show increased tau phosphorylation following okadaic acid 
treatment. D) Quantification shows that the amount of tau pulled down by BIN1-SH3-GST is 
reduced following okadaic acid treatment of primary neurons. Data is shown as percentage 
relative to the mean of controls (vehicle).  Following Shapiro-Wilk normality testing, the data 
were analysed using an unpaired T-test. Data shown are mean ± S.E.M, n=4. ****p<0.0001. 
E) Lysates from primary cortical neurons show reduced tau phosphorylation following 
treatment with 25 mM LiCl (+) for 4 hours relative to vehicle-treated neurons (-). BIN1-SH3-
GST pulldowns show that there was no difference in the amount of tau pulled down by BIN1-
SH3-GST following LiCl treatment relative to vehicle-treated conditions. F) Quantification 
shows no difference in the amount of tau from vehicle- or LiCl-treated neurons pulled down 
by BIN1-SH3-GST. Following Shapiro-Wilk normality testing, data were analysed using a 
non-parametric Mann-Whitney test. Data shown are mean ± S.E.M, n = 3. 
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Figure 5: BIN1 knockdown alters dendritic spine morphology. A) Primary cortical neurons 
transduced with BIN1 shRNA (BIN1) lentivirus or scrambled control shRNA (Scr) lentivirus 
at 5 DIV were transfected with a plasmid expressing eGFP and fixed at 23 DIV. Maximum 
intensity projections were generated from Z-stacks acquired using I-SIM super-resolution 
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imaging. Five to ten different neurons per condition were analysed in each of three separate 
experiments, one dendrite from each cell was selected randomly for spine quantification and 
all branches of that dendrite were analysed. Dendritic spines were classified as either filopodia 
or stubby, thin or mushroom spines (right). Bar charts show quantification of spine B) length, 
C) volume, D) density, E) head diameter, F) neck diameter, G) ratio of spine head to neck 
diameter, and percentage of H) stubby, I) thin, J) mushroom spines and K) filopodia. Data are 
mean ± S.E.M. and were analysed using a randomised block 2-way ANOVA. n=3. *p<0.05, 
**p<0.01. 
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Figure 6: BIN1 knockdown reduces basal and stimulated tau release. A) Cell lysates from 
21 DIV primary cortical neurons transduced with scrambled control shRNA (Scr) lentivirus or 
BIN1 shRNA (BIN1) lentivirus at 5 DIV were western blotted with antibodies against BIN1 
and total tau. B) Quantification shows no effect of BIN1 knockdown on intracellular tau 
amount. Shapiro-Wilk normality test demonstrated that the data were normally distributed, and 
so data were analysed using an unpaired T-test. C) Tau content in conditioned media from the 
same neurons was determined by ELISA. Extracellular tau amounts were quantified relative to 
intracellular tau from the same well, and the data shows reduced tau release upon BIN1 
knockdown. Shapiro-Wilk normality test demonstrated that the data were normally distributed, 
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so data were analysed using an unpaired T-test. D) Cells transduced as above were depolarised 
with 50 nM KCl (+) for 30 minutes, and the lysates were western blotted with antibodies 
against BIN1 and total tau. E) KCl treatment had no effect on intracellular tau amounts.  
Shapiro-Wilk normality test demonstrated that the data were normally distributed, so data were 
analysed using an unpaired T-test. F) Tau in conditioned media from KCl-stimulated cells was 
measured as described for basal conditions. Tau release from neurons in which BIN1 was 
knocked down was reduced upon neuron depolarisation with KCl. Shapiro-Wilk normality test 
demonstrated that the data were not normally distributed, so data were analysed using a Mann-
Whitney test. G) Lactate dehydrogenase amounts were measured in medium from unstimulated 
(-) or KCl- stimulated (+) primary cortical neurons transduced with scrambled control shRNA 
(Scr) lentivirus or BIN1 shRNA (BIN1) lentivirus as above, and show no effect of treatment 
on cell viability. Shapiro-Wilk normality test demonstrated that the data were not normally 
distributed, so data were analysed using a Kruskal-Wallis test with Dunn’s multiple 
comparison test. All graphs show mean ± S.E.M, n=7 (intracellular tau), n= 6 (tau 
release/intracellular tau, and lactate dehydrogenase assay). *p<0.05.  
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Table 1: Characteristics of temporal cortex tissue used in this study. Table shows details 
of sex, age, post-mortem delay (hours), Braak stage and Alzheimer’s disease diagnosis for 
cases from which frozen temporal cortex sections was obtained. 
 
Sex Age (years) Post-
mortem 
delay (hours) 
Braak stage Diagnosis 
F 74 64 II Control 
F 90 44 II Control 
F 73 27 I Control 
F 77 21 0 Control 
F 80 22 II Control 
M 68 60 II Control 
M 80 55 II-III Control 
M 90 45 - Control 
M 78 24 III Control 
F 92 9 II Control 
M 82 47 I Control 
F 84 34 I-II Control 
F 90 50 II Control 
M 66 52 - Control 
M 82 18 I/II Control 
M 91 48 IV Moderate 
Alzheimer’s 
disease 
M 88 79 III-IV Moderate 
Alzheimer’s 
disease 
F 95 47 IV Moderate 
Alzheimer’s 
disease 
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M 84 86 IV Moderate 
Alzheimer’s 
disease 
M 98 53 IV Moderate 
Alzheimer’s 
disease 
F 86 55.5 IV Moderate 
Alzheimer’s 
disease 
M 82 28 IV Moderate 
Alzheimer’s 
disease 
M 86 52.5 IV Moderate 
Alzheimer’s 
disease 
F 83 22 IV Moderate 
Alzheimer’s 
disease 
M 93 13.5 IV Moderate 
Alzheimer’s 
disease 
F 83 41.5 IV Moderate 
Alzheimer’s 
disease 
F 97 67.5 III-IV Moderate 
Alzheimer’s 
disease 
F 96 39 IV Moderate 
Alzheimer’s 
disease 
F 92 19.5 III Moderate 
Alzheimer’s 
disease 
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F 92 29.5 IV Moderate 
Alzheimer’s 
disease 
F 73 30 VI Severe 
Alzheimer’s 
disease 
F 84 27 VI Severe 
Alzheimer’s 
disease 
F 79 31 VI Severe 
Alzheimer’s 
disease 
M 86 38 VI Severe 
Alzheimer’s 
disease 
F 85 79 VI Severe 
Alzheimer’s 
disease 
M 67 39.5 VI Severe 
Alzheimer’s 
disease 
F 69 73 VI Severe 
Alzheimer’s 
disease 
F 89 38.5 VI Severe 
Alzheimer’s 
disease 
F 93 49 VI Severe 
Alzheimer’s 
disease 
M 84 67 VI Severe 
Alzheimer’s 
disease 
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F 81 20 VI Severe 
Alzheimer’s 
disease 
M 83 22 VI Severe 
Alzheimer’s 
disease 
F 81 17.5 VI Severe 
Alzheimer’s 
disease 
F 86 25 VI Severe 
Alzheimer’s 
disease 
M 66 41 VI Severe 
Alzheimer’s 
disease 
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Table 2. Summary of temporal cortex cases and controls used in this study. Table shows 
the percentage of control, moderate Alzheimer’s disease and severe Alzheimer’s disease 
cases that were female, the mean age at death (+/-SEM) and the mean post-mortem delay (+/- 
SEM). 
 
Disease stage Female (%) Age (years) 
Mean +/- SEM 
Post-mortem delay 
(hours) 
Mean +/- SEM 
Control 53.3 80.4 ± 2.07 38.1 ± 4.40 
Moderate 57.1 89.6 ± 1.42 45.3 ± 5.50 
Severe 64.2 80.9 ± 2.10 39.8 ± 5.00 
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SUPPLEMENTARY DATA 
Supplementary Figure 1 
 
Supplementary Figure 1: Fractionation of Alzheimer’s disease temporal cortex to isolate 
synaptoneurosomes A) Equal protein concentrations of total temporal cortex homogenates 
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together with cytoplasmic and synaptoneurosome fractions isolated from the same brain 
samples were western blotted using antibodies against PSD95, actin, and synaptophysin to 
confirm that synaptic proteins are found within the synaptoneurosome but not cytosolic 
fraction. B) To test for synaptic integrity, a subset of samples were western blotted using an 
antibody against the NMDA NR2B subunit which recognises full-length NR2B (top arrow 
head) and degradation products (bottom arrowhead). The ratio of the top/bottom bands are 
quantified in C and show reasonable preservation of synaptic integrity in these samples, with 
no differences between groups. Total homogenates, synaptoneurosome and cytoplasmic 
fractions of control (Braak stage 0-III), moderate (Braak stage III-IV) and severe (Braak stage 
V-VI) Alzheimer’s disease brain were immunoblotted and probed for neuron-specific enolase 
(NSE). Bar charts show quantification of NSE in D) total (n=13), E) synaptoneurosome (n=15) 
and F) cytoplasmic fractions (n=11) following normalisation to controls. There are no 
significant alterations in this neuronal marker between groups. Following D’Agostino and 
Pearson normality testing, data were analysed by Kruskal-Wallis test with Dunn’s multiple 
comparison test (total and cytoplasm) or one-way ANOVA with Tukey’s multiple comparisons 
test (synaptoneurosomes). Graphs show mean ± S.E.M. Correlation analysis of BIN1 and tau 
amounts in G) total homogenates (n=44), and H) synaptoneurosomes (n=45), and BIN1, and I) 
phosphorylated tau (pSer396/404, PHF1) in total homogenates (n=42) and J) 
synaptoneurosomes (n=45) shows no correlation between total tau or phosphorylated tau and 
BIN1 in these fractions. Colours in G, H, I and J represent mild (green), moderate (blue) and 
severe (purple) stage samples. 
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Supplementary Figure 2 
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Supplementary Figure 2: BIN1 localization and validation of BIN1 knockdown in cortical 
neurons. A) Lysates of equivalent protein concentration (as determined by Ponceau red 
staining of membranes) from primary cortical neurons transduced with scrambled control 
shRNA (Scr) lentivirus or BIN1 shRNA (BIN1) lentivirus at 5 DIV were western blotted for 
BIN1, total tau, tau phosphorylated at Ser396/404 (PHF1), tau dephosphorylated at 
Ser199/202/Thr205 (tau-1), PSD95, and synaptophysin. Quantification of western blots for B) 
total tau, C) PHF1, D) tau 1, E) PSD95, and F) synaptophysin. Data are expressed as a 
percentage of average control (Scr). Following Shapiro-Wilk normality testing total tau, tau1, 
PSD95, and synaptophysin were analysed using an un-paired T-test. PHF1 data were analysed 
by Mann-Whitney test. Graphs show the mean ± S.E.M of 3 (total tau, PHF1 tau and tau 1), 7 
(PSD95) or 6 (synaptophysin) independent experiments. G) Proximity ligation assays (PLA) 
were used to demonstrate interactions between endogenous BIN1 and tau in rat primary cortical 
neurons and to confirm BIN1 knockdown by BIN1 siRNA. Images show PLA signals (red) in 
neurons treated with Ctl (scrambled) siRNA indicating regions of BIN1-tau interactions. 
Strong PLA signals identified in the soma of neurons were markedly reduced upon BIN1 
siRNA knockdown, residual interactions likely occurring as a result of incomplete knockdown. 
Nuclei of cells were stained with Hoechst 33352 (blue) and the actin cytoskeleton was labelled 
with phalloidin (green). While phalloidin can stain glial cells as well as neurons, previous work 
has shown our cultures contain fewer than 4 % glial cells (Garwood et al., 2011), furthermore 
tau is not found in rodent glial cells and therefore we are confident that the interactions between 
BIN1 and tau are in neurons. Only trace levels of PLA signals were observed in controls lacking 
primary antibody or in primary cortical neurons treated with BIN1 siRNA. H) Bar chart shows 
significantly reduced PLA signal intensity/area in neurons exposed to BIN1 siRNA (BIN1) 
relative to non-targeting control (Ctl) siRNA at 19 DIV. Data were analysed using Mann-
Whitney tests. Data shown are mean ±S.E.M. n=3, *p<0.05. I) Instant SIM images show a 
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close association of some BIN1 puncta (ab54764, pink) with astrocytes (GFAP, yellow). J) 
Some BIN1 (ab54764, pink) close to synaptophysin (syp, green) puncta were found in 
association with the distal end of astrocyte processes (GFAP, yellow, open arrow heads), 
however many BIN1-synaptophysin pairs were not (closed arrow heads). 
  
  
 47 
Supplementary Figure 3 
 
Supplementary Figure 3: BIN1-SH3 binds to PXXP motifs in tau. A) Lysates from 
HEK293 cells transfected with empty vector (-) or 2N4R human tau (+) were incubated with 
BIN1-SH3-GST (SH3) glutathione beads, or GST- (GST) beads as a control. Lysates (input) 
and GST-bound proteins (pulldown) were probed on western blots with antibodies against total 
(phosphorylated and nonphosphorylated) tau or GST. Tau was pulled down by BIN1-SH3-
GST but not GST- only, no interactions were observed with GST-only and empty vector 
controls. B) Amino acid sequence 151-250 of human 2N4R tau in which the seven PxxP motifs 
are underlined, and prolines in these motifs that were mutated to alanine are indicated in 
lowercase and bold type.   
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Supplementary Figure 4
 
Supplementary Figure 4: Inhibiting casein-kinase 1 activity to reduce tau 
phosphorylation does not alter the interaction of tau with BIN1-SH3. A) Lysates from 21-
23 DIV primary cortical neurons show reduced tau phosphorylation following treatment with 
20 μM IC261 (+) for 4 hours relative to vehicle-treated neurons (-). BIN1-SH3-GST pulldowns 
show that there was no apparent difference in the amount of tau pulled down by BIN1-SH3-
GST following reduction of tau phosphorylation by IC261 treatment. B) Quantification of the 
amount of tau from vehicle- or IC261-treated neurons pulled down by BIN1-SH3-GST shown 
as percentage mean control (vehicle).  Following Shapiro-Wilk normality testing, data were 
analysed using a Mann-Whitney test. Data is mean ± S.E.M., n = 3.  
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Supplementary Figure 5 
 
Supplementary Figure 5: BIN1 Knockdown alters neuronal complexity. A) Primary 
cortical neurons transduced with BIN1 shRNA (BIN1) lentivirus or scrambled control shRNA 
(Scr) lentivirus at 5 DIV were transfected with a plasmid expressing eGFP and fixed at 23 DIV. 
Maximum intensity projections were generated from Z-stacks acquired using I-SIM super-
resolution imaging. Five to ten different neurons per condition were analysed in each of three 
separate experiments. The number of intersections at each radius were quantified (graph). 
Shapiro-Wilk test showed the data were normally distributed, data were analysed by One-way 
ANOVA with Sidak’s multiple comparisons test. B) Quantification of complexity of primary 
cortical neurons transduced with scrambled control shRNA (Scr) lentivirus or BIN1 shRNA 
(BIN1) lentivirus. Complexity was calculated as (sum of the terminal orders + number of 
terminals) * (total dendritic length/number of primary dendrites), where terminals is the 
number of branch endings, and terminal orders is the number of branches between the terminal 
and the cell body. Data are mean ± S.E.M. and were analysed using a randomised block 2-way 
ANOVA. n=3. Graphs show mean ±S.E.M of 3 independent experiments. *p<0.05, **p<0.01. 
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Supplementary methods 
Proximity Ligation Assays 
Proximity ligation assays were performed as described by us previously (Gomez-Suaga et al., 
2019) in 23DIV neurons using primary antibodies against BIN1 (ab54764, Abcam, Cambridge, 
UK) and total tau (Agilent, CA, USA). The actin cytoskeleton was labelled with phalloidin-
488 (Life Technologies, CA, USA), and nuclei were stained with 10 μgml-1 Hoescht-33342 
(Thermo Fischer Scientific). Image stacks covering the whole volume of each cell were 
acquired using a Nikon Eclipse Ti-E microscope and images were analysed using Fiji. Z-stacks 
were converted to maximum intensity projections, and the phalloidin signal used to identify 
cell outlines. The intensity of duo-link signals in each cell was quantified using image J and is 
expressed as a proportion of cell area.  
 
Analysis of neuronal complexity 
For analysis of dendrite structure, neurons at 22 DIV were transfected with an eGFP-N2 
plasmid (Clontech, Kyoto, Japan) using lipofectamine 2000 for 24 hours, fixed and the GFP 
signal imaged using a Nikon Eclipse Ti-2 inverted microscope with Vt-iSIM scan head. 3x3 
large image stacks were acquired covering the entire volume of the neuron, with 0.2 μm 
between each image in the Z plane. NeurolucidaTM software (MBF Bioscience, VT, USA) was 
used to trace neurons and detect, classify and quantify the dendritic spines, and perform Scholl 
analysis. Neuronal complexity was determined as (sum of terminal orders + number of 
terminals) * (total dendritic length / number of primary dendrites]), where terminals is the 
number of branch endings, and terminal order is the number of branches between the terminal 
and the cell body (Pillai et al., 2012). 
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Abbreviated Summary 
Polymorphisms associated with BIN1 increase risk of Alzheimer’s disease. We show that in 
Alzheimer’s disease cortex BIN1 is lost from the cytoplasmic fraction and phosphorylated 
tau accumulates at synapses. This can be mimicked by BIN1 knockdown in cultured neurons, 
which also caused disrupted dendritic morphology and tau release.  
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